Pharmicell Co

Pharmicell Co EBIT per Share

The EBIT per Share of Pharmicell Co (005690.KS) as of Nov 5, 2026 is 572.25 KRW. In the previous year, EBIT per Share was 77.66 KRW — a change of 636.83% (higher).

EBIT per Share

572.25KRW

YoY

636.83%

Last updated:

EBIT per Share of Pharmicell Co is 2025 572.25 KRW. EBIT per Share of Pharmicell Co was 2024 77.66 KRW. It decreases by 636.83% higher compared to the previous year.

The Pharmicell Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
120.67 KRW
Jan 1, 2021
182.44 KRW
Jan 1, 2022
148.02 KRW
Jan 1, 2023
21.62 KRW
Jan 1, 2024
77.66 KRW
Jan 1, 2025
572.25 KRW
Jan 1, 2026 (e)
1,257.04 KRW
Jan 1, 2027 (e)
1,553.59 KRW
The Pharmicell Co EBIT per Share history
YEAREBIT per ShareYoY
est1,553.59KRW+23.59%
est1,257.04KRW+119.67%
572.25KRW+636.83%
77.66KRW+259.23%
21.62KRW-85.39%
148.02KRW-18.86%
182.44KRW+51.19%
120.67KRW+268.38%
32.76KRW+654.71%
4.34KRW-105.83%
-74.39KRW+139.01%
-31.12KRW-69.06%
-100.58KRW-45.04%
-183.00KRW-1.39%
-185.58KRW-21.93%
-237.71KRW-7.34%
-256.55KRW+46.79%
-174.78KRW+12.44%
-155.44KRW-16.23%
-185.56KRW-46.06%
-344.00KRW+1.78%
-338.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmicell Co Stock analysis

What does Pharmicell Co do? Pharmicell Co., Ltd. develops stem cell-based pharmaceuticals and technologies, focusing on stem cell therapeutic drugs and stem cell-based cosmetics. The company provides stem cell storage services and supplies mesenchymal stem cells (MSCs) for research purposes. It also operates a fashion business under the brand names Religion and Day, offering women’s and men’s apparel. The company merged with its wholly owned subsidiary on March 31, 2013, which was primarily engaged in medicine manufacturing and sales. Pharmicell generates revenue through its biopharmaceutical division, selling stem cell therapeutic drugs and cosmetics, as well as stem cell storage services and MSCs for research. The fashion business contributes through the sale of apparel under the Religion and Day brands. The primary buyers for pharmaceutical products include healthcare providers and research institutions, while the fashion segment targets consumers purchasing women’s and men’s clothing. The company’s segments are biopharmaceuticals, stem cell services, and fashion apparel. The biopharmaceutical business develops and manufactures stem cell-based drugs and cosmetics, with MSCs used in research areas. The fashion segment operates under the brand names Religion and Day, providing women’s and men’s apparel. The company’s revenue streams are derived from the sale of therapeutic drugs, cosmetics, stem cell storage, MSCs for research, and apparel sales. The merged subsidiary’s medicine manufacturing and sales activity complements the core biopharmaceutical operations. Pharmicell Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharmicell Co stock

EBIT per Share of Pharmicell Co is 572.25 KRW in 2025.

EBIT per Share of Pharmicell Co changed from 77.66 KRW to 572.25 KRW, representing a 636.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Pharmicell Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Pharmicell Co

All Key Metrics — Pharmicell Co